“Since our founding in 2007, CanLiv has made extraordinary strides in connecting key researchers with one another, and focusing their work on these little-understood cancers." Dr. Melanie Thomas
Charleston, SC (PRWEB) March 28, 2012
Translational science – cross disciplinary scientific research that seeks practical applications that help people – will be the focus of the second CanLiv Foundation (CanLiv.org) symposium. Scores of researchers, cancer doctors, patient advocates, foundation experts and others are expected to gather June 22 in Alexandria, VA to share insight on the causes and treatments of “orphan” cancers of the gallbladder and bile ducts.
CanLiv will also use the symposium to announce a major advance in their efforts to foster more research and treatment options for those facing these “orphan” hepatobiliary cancers.
“Since our founding in 2007, CanLiv has made extraordinary strides in connecting key researchers with one another, and focusing their work on these little-understood cancers,” said Dr. Melanie Thomas, President of CanLiv and Associate Director of Clinical Investigations at Hollings Cancer Center, Medical University of South Carolina. “Our focus now is going to be on breaking down barriers, sharing discoveries and supporting one another across disciplines and across time zones.”
The Symposium will be opened with an inspirational address by Dr. John Niederhuber, a renowned liver surgeon, former Director of the National Cancer Institute (2004-2010) and CEO of Inova Translational Medicine Institute.
Keynoting the symposium will be Margaret Anderson, Executive Director of Faster Cures, a Washington, DC-based center of the Milken Institute whose purpose is to speed the time it takes to turn lab discoveries into patient therapies. Her topic: Creating a Successful Research Consortium: Lessons, Pitfalls, Advice.
While CanLiv’s focus includes cancers of the liver, gallbladder and bile ducts, this year’s symposium will concentrate mostly on the biliary tract and gallbladder. Sessions include: Genomic Basis for Targeted Therapies in Cholangiocarcinoma, by Snorri Thorgiersson, M.D., Ph.D. NIH; Molecular Profiling of Gallbladder Cancer, Juan Carlos Roa M.D., Universidad de la Frontera, Chile; and Broad –based Genotyping of Cholangiocarcinoma and Novel Pre-clinical Models, Lewis Roberts, M.D., Ph.D., Mayo Clinic, Rochester MN.
The CanLiv Foundation was created by a group of cancer researchers on several continents who were all struck by the absence of knowledge and shared insights related to hepatobiliary cancers (liver, gallbladder and bile ducts). Since 2007, they have formalized a program of research and information-sharing, created a patient-focused website with educational materials and more, and shined a light on cancers that affect millions of patients worldwide.